AccuGenomics specializes in advanced genomic technologies that enhance the accuracy and sensitivity of next-generation sequencing (NGS) applications. Their proprietary SNAQ™-SEQ internal standards are designed to improve the performance of NGS assays by providing spike-in controls that help mitigate false positives and negatives. This technology allows for direct measurements of technical and systemic errors, ensuring that the results reflect the true performance of each sample tested. By utilizing SNAQ-SEQ, researchers can achieve digital PCR-like accuracy in RNA sequencing, enabling the simultaneous monitoring of hundreds of RNA biomarkers across a wide dynamic range.

In addition to SNAQ-SEQ, AccuGenomics offers customized Accukits™ tailored for various applications, including the detection of circulating tumor DNA (ctDNA), copy number variants (CNVs), and biocontaminants. These kits are designed to enhance the sensitivity and specificity of assays, providing reliable results in complex biological samples. The company’s focus on developing innovative quality control standards and internal controls positions them as a leader in the field of genomic diagnostics, particularly in areas such as cancer research and infectious disease monitoring.

United States

AccuGenomics is a biotechnology company that specializes in a unique spike-in control technology to enhance the accuracy of clinical sequencing tests for low abundance biomarkers and infectious pathogens.

AccuGenomics

Company Details